Pyridam Farma (PYFA) Records 77.3% Revenue Increase in Q3/2025, Driven by Innovative Product Lines & Services

Jakarta, November 5, 2025 – PT Pyridam Farma Tbk. (PYFA) recorded solid consolidated year-to-date revenue of Rp2.06 trillion as of the end of the third quarter of 2025. In comparison to the same period last year (YoY), this value represents a significant increase of 77.3%, up from last year’s revenue of Rp1.16 trillion.

Citing the Company’s financial report, pure operational cash performance as reflected in EBITDA showed a very significant improvement. The Company’s EBITDA was recorded positive at Rp133.32 billion in 9M 2025, a 100.6% increase compared to Rp66.44 billion in the same period of 2024. This strengthening was supported by a 77.3% annual increase in revenue, proving that the Company’s core business, including contributions from new entities, remains strong and efficient.

In line with business expansion and post-acquisition integration, the cost of goods sold (COGS) was recorded at Rp1.64 trillion. Nevertheless, the Company successfully maintained efficiency and profitability at a fundamental level, evidenced by a 41.28% (YoY) increase in gross profit to Rp417.86 billion.

PYFA Finance Director, Sinta Ningsih, remains optimistic that the Company’s performance in the coming periods will continue to strengthen. This is supported by the full operational consolidation of key factories, including the new Probiotec facility in Kemps Creek, Australia, as well as the preparation for full operations at the Ethica factory in Cikarang, West Java.

“The increase in cost of goods sold is an anticipated part of our integration and expansion strategy. We invite stakeholders to look at the bigger picture, as the integration process is still ongoing and the Company’s future growth potential remains very strong. We have successfully optimized operations at the Probiotec factory in Kemps Creek, supported by TGA and Halal AIHCO certifications which open access to global markets. Furthermore, domestically, the construction of the Ethica factory is proceeding according to plan and is expected to be completed in early 2026.”

This performance growth was driven by strengthening across all of the Company’s business pillars. The main pillar of growth came from the CDMO (Contract Development and Manufacturing Organization) segment, reflected in various international principals that have partnered with PYFA. Global pharmaceutical names include Eli Lilly (USA) for Cialis, Humalog, and Humulin; Amgen (USA) for Corora, Amgevita, and Xgeva; Lundbeck (Denmark) for Abixa, Brintellix, and Vyepti; Merz Pharma (Germany) for Xeomin and Hepamerz; as well as Polysan (Russia) for Reamberin and Cytoflavin.

Furthermore, the prescription drug segment showed increasingly strong sales figures, boosted by high sales from various innovative product portfolios and “first-in-Indonesia” products categorized as New Chemical Entities (NCE). Additionally, the Over-the-Counter (OTC) segment also showed significant growth. Through its PYFAHealth and PYFABeauty lines, the Company continues to expand the reach of its flagship products, which are now more accessible to consumers through leading pharmacy networks and health and beauty retailers such as Century, Boots, Apotek Roxy, and VIVA Apotek.

As the year-end approaches, a factor that will further drive future sales growth is the full utilization of the factory expansion owned by PYFA’s subsidiary, Probiotec, in Kemps Creek, which became fully operational starting November 2025. Additionally, Probiotec has officially obtained licenses from the Therapeutic Goods Administration (TGA) and Halal AIHCO certification, signaling that Probiotec can conduct exports for global expansion due to its international standard certification.

With strengthening operational fundamentals and an integration process proceeding according to plan, PYFA believes in solid growth prospects for 2026. The Company is committed to completing this strategic integration to create sustainable added value for all shareholders.